Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Mucinous carcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44351   clinical trials with a EudraCT protocol, of which   7378   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: Mucinous carcinoma. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2010-023345-30 Sponsor Protocol Number: RAD-IPMT Start Date*: 2010-11-18
    Sponsor Name:U.L.S.S. 9 DI TREVISO
    Full Title: Prospective spontaneous cross-over study on pancreatic T1/T2 enhancement in patients with IPMT: comparison Omniscan-Dotarem
    Medical condition: Pancreatic intraductal papillary mucinous tumor
    Disease: Version SOC Term Classification Code Term Level
    9.1 10004609 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000837-23 Sponsor Protocol Number: UCL07/095 Start Date*: 2009-02-19
    Sponsor Name:University College London
    Full Title: mEOC: A GCIG Intergroup multicentre trial of open label carboplatin & paclitaxel +/- bevacizumab compared with oxaliplatin & capecitabine +/- bevacizumab as first line chemotherapy in patients with...
    Medical condition: Mucinous ovarian cancer, stages II-IV and stage I recurrent
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) FI (Prematurely Ended) IT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-003512-37 Sponsor Protocol Number: OC-AP-ICG-IV-2 Start Date*: 2014-10-13
    Sponsor Name:Jules Bordet Institute
    Full Title: Study of the (intravenously injected) ICG (Indocyanine Green) imaging of tumoral implants in patients with peritoneal carcinomatosis from colorectal origin.
    Medical condition: Imaging of tumours and their metastasis after intravenous injection of Indocyanine Green to patients with peritoneal carcinomatosis from colorectal cancer.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002888-10 Sponsor Protocol Number: SYD985.003 Start Date*: 2020-03-25
    Sponsor Name:Byondis BV
    Full Title: A single-arm phase II trial to evaluate the safety and efficacy of the antibody-drug conjugate SYD985 in patients with HER2-expressing recurrent, advanced or metastatic endometrial carcinoma who pr...
    Medical condition: Recurrent, Advanced or Metastatic Endometrial Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10014743 Endometrial carcinoma LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002764-79 Sponsor Protocol Number: RESCUE Start Date*: 2023-04-13
    Sponsor Name:Fundació Clínic per a la Recerca Biomèdica
    Full Title: Diagnostic yield of Endoscopic aspiration of duodenopancreatic juice after secretin stimulation (ADPJ-secr-) vs endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for molecular analysis ...
    Medical condition: Intraductal papillary mucinous intraductal neoplasia
    Disease: Version SOC Term Classification Code Term Level
    25.1 100000004864 10070999 Intraductal papillary mucinous neoplasm LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-005872-29 Sponsor Protocol Number: MORAb-003-004 Start Date*: 2009-09-24
    Sponsor Name:Eisai Limited
    Full Title: A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Weekly Farletuzumab (MORAb-003) in Combination with Carboplatin and Taxane in Subjects with Plati...
    Medical condition: First relapse of platinum-sensitive non-mucinous epithelial ovarian cancer including primary peritoneal or fallopian tube malignancies
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033160 Ovarian epithelial cancer recurrent PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Prematurely Ended) PT (Prematurely Ended) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) HU (Prematurely Ended) IT (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) FR (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023124-24 Sponsor Protocol Number: LUMCCHIP Start Date*: 2011-03-02
    Sponsor Name:Academisch Ziekenhuis Leiden acting under the name of Leids Universitair Medisch Centrum
    Full Title: Chemo-Immunotherapy, gemcitabine with pegylated interferon alpha-2b (Peg-Intron) with and without p53 synthetic long peptide (p53 SLP) vaccine, for patients with platinum resistant ovarian cancer. ...
    Medical condition: Recurrent platinum resistant, p53 positive ovarian cancer.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-003792-63 Sponsor Protocol Number: UCL/17/0629 Start Date*: 2018-10-23
    Sponsor Name:University College London
    Full Title: Phase II trial of maintenance pembrolizumab following weekly paclitaxel for recurrent ovarian, fallopian tube or peritoneal cancer
    Medical condition: recurrent ovarian/fallopian tube or primary non-mucinous peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066697 Ovarian cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-003844-31 Sponsor Protocol Number: H6Q-MC-S064 Start Date*: 2007-11-28
    Sponsor Name:Eli Lilly and Company limited
    Full Title: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study of Enzastaurin with 5 FU/LV plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colorectal Cancer
    Medical condition: Locally advanced or metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061451 Colorectal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) FR (Completed) IT (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-001875-37 Sponsor Protocol Number: AK/RH/22498/1 Start Date*: 2007-08-24
    Sponsor Name:University of Warwick
    Full Title: Neo-ESCAPE (Neoadjuvant Extended Sequential Chemotherapy with Adjuvant Postoperative treatment for Epithelial non-mucinous advanced inoperable peritoneal malignancy): a randomised feasibility study...
    Medical condition: Epithelial non-mucinous advanced inoperable peritoneal malignancy (ovarian carcinoma, ovarian carcinosarcoma, fallopian tube or primary peritoneal carcinoma)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2006-003466-34 Sponsor Protocol Number: M06OVH Start Date*: 2006-12-14
    Sponsor Name:NKI-AVL
    Full Title: Phase III randomised clinical trial for stage III ovarian carcinoma randomising between secondary debulking surgery with or without hyperthermic intraperitoneal chemotherapy (OVHIPEC-I)
    Medical condition: ovarian carcinoma or peritoneal cancer (PPSC) or fallopian tube carcinoma FIGO Stage III
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001325-24 Sponsor Protocol Number: SOV03 Start Date*: 2013-08-30
    Sponsor Name:SOTIO a.s.
    Full Title: A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy in women with relapsed platinum resistant epith...
    Medical condition: epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    16.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001323-38 Sponsor Protocol Number: SOV02 Start Date*: 2013-08-30
    Sponsor Name:SOTIO a.s.
    Full Title: A randomized, open-label, parallel group, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to standard chemotherapy (carboplatin and gemcitabine) in women with rel...
    Medical condition: epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: CZ (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000553-23 Sponsor Protocol Number: GBG66 Start Date*: 2011-09-29
    Sponsor Name:German Breast Group GBG Forschungsgesellschaft mbH (Sponsor nach GCP)
    Full Title: A randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer
    Medical condition: patients with triple-negative breast cancer, patients with HER2-positive early breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10021976 Inflammatory breast cancer stage IV LLT
    14.1 100000004864 10063104 Tubular breast cancer stage II LLT
    14.1 100000004864 10065430 HER-2 positive breast cancer LLT
    14.1 100000004864 10022882 Invasive ductal breast cancer LLT
    14.1 100000004864 10028061 Mucinous breast cancer stage II LLT
    14.1 100000004864 10006188 Breast cancer female NOS LLT
    14.1 100000004864 10063105 Tubular breast cancer stage III LLT
    14.1 100000004864 10021974 Inflammatory breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004730-42 Sponsor Protocol Number: IQVIA-ODYS-001-LZA45541 Start Date*: 2022-10-24
    Sponsor Name:IQVIA RDS FRANCE SAS
    Full Title: Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in c...
    Medical condition: Long term potential effect of repeated exposure to either a linear or a macrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 in motor and cognitive function among ne...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070999 Intraductal papillary mucinous neoplasm PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    20.1 100000004871 10008953 Chronic liver disease LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061451 Colorectal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060862 Prostate cancer PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) IT (Trial now transitioned) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-000879-26 Sponsor Protocol Number: 311602-Amendment 1 Start Date*: 2008-08-07
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: (REASON) double-blind, Randomized phase II study to Evaluate the safety and efficacy of Acetyl-l-carnitine in the prevention of SagOpilone-induced peripheral Neuropathy.
    Medical condition: - Advanced refractory or relapsed ovarian cancer - Patients with metastatic hormone-refractory prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NL (Completed) BE (Completed) GB (Completed) DE (Completed) ES (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-001322-26 Sponsor Protocol Number: SOV01 Start Date*: 2013-12-02
    Sponsor Name:SOTIO a.s.
    Full Title: A randomized, open-label, three-arm, multi-center Phase II clinical trial evaluating effect of addition of DCVAC/OvCa to first line standard chemotherapy (carboplatin and paclitaxel) in women with ...
    Medical condition: epithelial ovarian carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2006-006950-81 Sponsor Protocol Number: KTN32313R Start Date*: 2007-09-25
    Sponsor Name:BioNumerik Pharmaceuticals, Inc.
    Full Title: A PHASE 3 STUDY OF SAFETY AND EFFICACY OF KARENITECIN VERSUS TOPOTECAN ADMINISTERED FOR 5 CONSECUTIVE DAYS EVERY 3 WEEKS IN PATIENTS WITH ADVANCED EPITHELIAL OVARIAN CANCER
    Medical condition: advanced epithelial ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066697 Ovarian cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-011400-33 Sponsor Protocol Number: MO22224 Start Date*: 2009-08-12
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or...
    Medical condition: Platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061344 Peritoneal neoplasm PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10016180 Fallopian tube cancer PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) ES (Completed) PT (Completed) DE (Completed) IT (Completed) FR (Completed) DK (Completed) NL (Completed) BE (Completed) FI (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000847-25 Sponsor Protocol Number: EMR63325-013 Start Date*: 2011-07-04
    Sponsor Name:Merck KGaA
    Full Title: A multi-center, randomized, open-label, mechanism of action trial on the biological effects of the therapeutic cancer vaccine Stimuvax® (L-BLP25) in rectal cancer subjects undergoing neoadjuvant ch...
    Medical condition: Rectal cancer subjects undergoing neoadjuvant chemoradiotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10038043 Rectal cancer Duke's C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) DE (Completed) NL (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jul 20 18:04:44 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA